Thursday 16 October, 2025
Background: Joint models of longitudinal process and time to event data have recently gained attention specially for providing individualized dynamic…
Read moreOral: Drug/Disease Modelling
Machine learning combined to mechanistic modeling of differential effects of neoadjuvant sunitinib on primary tumor and metastatic growth
Thursday 16 October, 2025
Introduction: Despite proven clinical action of angiogenic inhibitors [1], recent experimental evidence also suggests differential effects of these drugs on…
Read moreA new approach to predict PFS in Ovarian Cancer based on tumor growth dynamics.
Thursday 16 October, 2025
Objectives: Progression free survival (PFS) is a surrogate efficacy endpoint that is being used for regulatory approval of investigational drugs…
Read moreDynamics of the humoral immune response to a two-dose heterologous vaccine regimen against Ebola virus.
Thursday 16 October, 2025
Introduction: The two-dose heterologous vaccine regimen Ad26.ZEBOV,MVA-BN-Filo against Ebola virus has been evaluated in multiple clinical trials. However, the long-term…
Read moreAssociation between tumor size kinetics and survival in advanced urothelial carcinoma patients treated with atezolizumab: implication for patient’s follow-up
Thursday 16 October, 2025
Context: Immune-oncology is revolutionizing cancer treatment, but the association between treatment response and survival remains poorly understood. The response kinetics,…
Read moreIntegrated efficacy-safety QSP model of acute myeloid leukemia (AML) generates insights into the role of clinical dose schedules on cytopenia
Thursday 16 October, 2025
Introduction: Acute Myeloid Leukemia (AML) is an aggressive hematological malignancy, characterized by an accumulation of leukemic blast cells in the…
Read moreBody composition and drug exposure in adipose tissue are key for antibiotic dose-individualisation in obese individuals
Thursday 16 October, 2025
Objectives: The introduction of model-informed precision dosing (MIPD) promises a shift from the “one-size-fits-all” paradigm in antimicrobial dosing. Yet, the…
Read moreCombination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy
Thursday 16 October, 2025
Objectives: Bacteriophage (phage) therapy provides an attractive option to the increasing failure of antibiotics treatments. Phages are viruses that specifically…
Read moreStratified medicine approaches for drug susceptible tuberculosis patients
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) kills more people than any other infectious disease. All current approaches to TB treatment are based on…
Read moreModel-based individual managing of thrombocytopenia during multi-cyclic chemotherapy
Thursday 16 October, 2025
Objectives: Thrombocytopenia is a major side-effect of cytotoxic cancer therapies. The development of individual therapy adaptations is a non-trivial task since thrombocytopenic…
Read more